Indication: Invasive Aspergillosis or Invasive Mucormycosis
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy andPharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects
Sub-indication: Invasive Aspergillosis or Invasive Mucormycosis
Principal Investigator: Victoria A Statler, M.D.Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine
Sponsor: Astellas Pharma Global Development Inc.